



Article (refereed) - postprint

Boxall, A.B.A.; Keller, V.D.J.; Straub, J.O.; Monteiro, S.C.; Fussell, R.; Williams, R.J. 2014. **Exploiting monitoring data in environmental exposure modelling and risk assessment of pharmaceuticals.**

Copyright © 2014 Elsevier Ltd.

This version available <http://nora.nerc.ac.uk/508154/>

NERC has developed NORA to enable users to access research outputs wholly or partially funded by NERC. Copyright and other rights for material on this site are retained by the rights owners. Users should read the terms and conditions of use of this material at <http://nora.nerc.ac.uk/policies.html#access>

NOTICE: this is the author's version of a work that was accepted for publication in *Environment International*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Environment International* (2014), 73. 176-185. [10.1016/j.envint.2014.07.018](https://doi.org/10.1016/j.envint.2014.07.018)

www.elsevier.com/

Contact CEH NORA team at
noraceh@ceh.ac.uk

1 **Exploiting Monitoring Data in Environmental Exposure Modelling and Risk**
2 **Assessment of Pharmaceuticals**

3 Boxall, A.B.A^{1*}, Keller, V.D.J.², Straub, J.O.³, Monteiro, S.C.⁴, Fussell, R.⁴, Williams, R.J.²

4

5 ¹ – Environment Department, University of York, Heslington, York, UK, YO10 5DD

6 ² – Centre for Ecology and Hydrology, Wallingford, UK, OX10 8BB

7 ³ – F.Hoffmann-La Roche Ltd, CH–4070 Basle, Switzerland

8 ⁴ – Food and Environment Research Agency, Sand Hutton, York, UK, YO41 1Z

9

10 * - corresponding author: Telephone 01904 434791; email Alistair.boxall@york.ac.uk

11

12

13

14 **Abstract**

15 In order to establish the environmental impact of an active pharmaceutical ingredient (API),
16 good information on the level of exposure in surface waters is needed. Exposure
17 concentrations are typically estimated using information on the usage of an API as well as
18 removal rates in the patient, the wastewater system and in surface waters. These input data
19 are often highly variable and difficult to obtain, so model estimates often do not agree with
20 measurements made in the field. In this paper we present an approach which uses inverse
21 modelling to estimate overall removal rates of pharmaceuticals at the catchment scale using a
22 hydrological model as well as prescription and monitoring data for a few representative sites
23 for a country or region. These overall removal rates are then used to model exposure across
24 the broader landscape. Evaluation of this approach for APIs in surface waters across England
25 and Wales showed good agreement between modelled exposure distributions and available
26 monitoring data. Use of the approach, alongside estimates of predicted no-effect
27 concentrations for the 12 study compounds, to assess risk of the APIs across the UK
28 landscape, indicated that, for most of the compounds, risks to aquatic life were low.
29 However, ibuprofen was predicted to pose an unacceptable risk in 49.5% of the river reaches
30 studied. For diclofenac, predicted exposure concentrations were also compared to the
31 Environmental Quality Standard previously proposed by the European Commission and 4.5%
32 of river reaches were predicted to exceed this concentration. While the current study focused
33 on pharmaceuticals, the approach could also be valuable in assessing the risks of other ‘down
34 the drain’ chemicals and could help inform our understanding of the important dissipation
35 processes for pharmaceuticals in the pathway from the patient to ecological receptors.

36

37 **Key words**

38 Active pharmaceutical ingredient, inverse modelling, ibuprofen, diclofenac

39

40 **Introduction**

41

42 During the life cycle of a pharmaceutical product, Active Pharmaceutical Ingredients (APIs)
43 may be released to the natural environment (Daughton and Ternes, 1999; Boxall, 2004) and a
44 wide range of APIs have been detected in surface waters (Hirsch *et al.*, 1999; Kolpin *et al.*,
45 2002; Monteiro and Boxall, 2010). Even though the reported concentrations are generally low
46 (i.e. sub- $\mu\text{g/l}$), questions have been raised over the potential impacts of APIs in the
47 environment on flora and fauna and human health. Environmental risk assessments are also
48 now required in many regions as part of the marketing authorisation process of a new API
49 (Breton and Boxall, 2003). In order to establish the risks of APIs, it is essential to have a
50 good understanding of the levels of exposure that occur in natural systems.

51 A range of exposure modelling approaches is currently being applied in the assessment of the
52 environmental risks of APIs. These include simple deterministic algorithms through to more
53 complex models such as the GREAT-ER, PhATE and LF2000-WQX models (EMA, 2006;
54 Schowanek and Webb, 2002; Schwab *et al.*, 2005; Williams *et al.*, 2009) which use data on
55 flow in rivers to estimate how APIs will be distributed within river catchments. In order to
56 accurately estimate concentrations in the environment, these models traditionally require
57 comprehensive information on the usage of an API within the system of interest, the extent of
58 metabolism of the API within treated humans and the degree of removal in wastewater
59 treatment processes and in receiving waters.

60 Many countries collate detailed information on the quantities of APIs used. For example, in
61 the UK, the National Health Service collect monthly information on the number of
62 prescriptions made for different products in different regions. From this freely available
63 information, it is possible to determine the amounts of different APIs prescribed in an area
64 over time. Similar systems are in place in Denmark, Germany and Australia. However, the
65 estimation of API usage, based on prescription volumes, may over-estimate what is actually

66 released to the environment. Over half of patients store unused medicines in their home as a
67 consequence of dosage changes, discontinuation of the medication due to, for example, the
68 occurrence of adverse side effects, or because the medications have reached their expiry date.
69 It is estimated that anywhere between 3 and 65% of prescribed pharmaceuticals are not used
70 and many of these will ultimately be returned to the pharmacist or disposed of to landfill
71 (Seehusen and Edwards, 2006; Musson and Townsend, 2009).

72 While numerous publications are available on the metabolism of APIs, the results of these
73 studies can be highly variable. For example, for cyclophosphamide (one of the APIs
74 investigated in the current study), amounts excreted are reported to range from 2 to 25% of
75 the applied dose (Bagley *et al.*, 1973). The observed differences are probably explained by
76 genomically distinct metabolising capacities as well as differences in race, sex, age and
77 health status of the studied subjects, all of which are known to affect the route and rate of
78 metabolism (Dorne, 2010). The method of administration, previous exposure of a patient to
79 the pharmaceutical and simultaneous exposure to other APIs and xenobiotics can also affect
80 the degree of metabolism.

81 For many APIs, no data exist on removal in wastewater treatment. In instances where data are
82 available, variations can also be seen in the reported removal efficiencies (Sipma *et al.*,
83 2010). These variations can be explained by differences in technologies used at different
84 treatment works and differences in operating parameters. Some metabolites may also be re-
85 converted back to the parent compound in wastewater treatment (Heberer *et al.*, 2002). In
86 large catchments it is likely that numerous treatment technologies will be in use and that
87 these will vary in size and performance, so a variety of removal rates may need to be
88 employed in the modelling. The fate of substances in the sewer system is also unknown.
89 Finally, available data on dissipation of APIs in receiving waters is mostly generated under
90 controlled laboratory conditions and dissipation in natural aquatic systems is often much

91 slower than in the laboratory (Fono *et al.*, 2006). When all of these different factors are
92 considered, it is perhaps not surprising that the selection of the input parameters for exposure
93 modelling for APIs can be challenging and that, while some exposure modelling of this type
94 has been successful for some contaminants (Ort *et al.*, 2009), predictions do not always agree
95 with observed measurements of APIs in the field (Metcalf *et al.*, 2008).

96 One approach to overcome the problem of the parameter selection process is to use
97 monitoring data alongside inverse modelling to derive model input parameters. In this
98 approach, data on measured concentrations of APIs within a study system are used in the
99 models to back calculate one or more model input parameter. The derived parameters can
100 then be employed to model exposure in other scenarios. The advantage of this approach in
101 API exposure modelling is that it accounts for variability in factors such as metabolism of
102 APIs within the population in the catchment; dissipation in the sewer network; effects of
103 different types of treatment technologies that are employed; and the different dissipation
104 processes that occur in surface waters. Inverse modelling, based on data on environmental
105 occurrence, has already successfully been used to estimate usage of illicit drugs for different
106 regions around the world (Zuccato *et al.*, 2011) and emissions and half-lives of selected APIs
107 into/in European surface waters (Pistocchi *et al.*, 2012).

108 In this paper we present and evaluate a combined monitoring and modelling approach that
109 uses prescription and monitoring data to estimate removal of pharmaceuticals between the
110 point of use and emission into surface waters. We then show how the removal estimates can
111 be used to estimate concentration distributions for API in water bodies at the landscape scale.
112 We illustrate the utility of the approach by assessing the risks of 12 commonly used APIs
113 across surface waters in England and Wales.

114 **1. Methods**

115 *1.1. Monitoring data*

116 The measured data on concentrations of APIs in surface waters was taken from a recent study
117 into the occurrence of APIs in surface and drinking waters in England and Wales (Boxall *et*
118 *al.*, 2012a). The twelve study APIs (Table 1) covered a range of chemical classes and varied
119 in terms of their physico-chemical properties. The study was carried out at four catchments,
120 which varied in terms of the population served and in the type of wastewater treatment
121 technologies employed (Table 2). Triplicate samples of surface water (2.5 L) were taken from
122 a single point in each catchment every 4 weeks for a period of 12 months. Following
123 collection, these were immediately transported back to the laboratory where they were
124 extracted onto HLB solid phase extraction cartridges before being analysed by LC-MS/MS
125 using a Waters Acquity Ultra-Performance Liquid Chromatography (UPLC) system (Waters,
126 Milford MA, US) fitted with a UPLC HSS T3 C18 column. Gradient elution was used with
127 mobile phases consisting of 5 mM ammonium acetate in water and methanol. Concentrations
128 were determined by comparison of peak areas with those of known matrix-matched
129 standards. For a number of analytes (atenolol, carbamazepine, fluoxetine and ibuprofen),
130 internal standards, comprising the deuterated form of the compound, were used to correct for
131 losses during the extraction process and/or suppression or enhancement of the MS signal. In
132 the event that internal standards were not available, sample over-spiking at a range of
133 concentrations was used to assess recovery of a compound. Seven of the 12 study compounds
134 were detected in surface waters at sub- $\mu\text{g/l}$ concentrations. Mean concentrations and
135 concentration ranges are shown in Table 1.

136

137 *1.2. Model Description*

138 The modelling was carried out using the LF2000-WQX model (Williams *et al.*, 2009), which
139 is a spatially-based modelling framework that has been widely applied to a number of
140 chemicals discharged down-the-drain (Williams *et al.*, 2009; Rowney *et al.*, 2009; Price *et al.*,

141 2010a and b; Janna *et al.*, 2011) and so only the parts salient to this analysis will be described
142 here. LF2000-WQX is the water quality extension model to the Low Flows 2000 (LF2000)
143 software system (Young *et al.*, 2003; Environment Agency, 2004), which is a geographical
144 information system (GIS) based decision support tool designed to estimate river flows at
145 ungauged sites. It combines hydrological models estimating the magnitude and variability of
146 flows across a catchment with a water quality model. The water quality model is driven by
147 discharges from sewage treatment plants (STPs), the locations of which are preset in the
148 model along with data describing the population served, treatment type and dry weather flow
149 of each works. The outputs of the model are mean and 90th and 95th percentile
150 concentrations for each river reach within the catchment being modelled.

151 Calculation of concentrations in river reaches is based on a simple mass balance mixing
152 equation which is applied in an iterative Monte Carlo simulation using the method of
153 combining distributions proposed by Warn and Brew (Warn and Brew, 1980). Point-source
154 effluent emissions are combined with reach-specific flow statistics to calculate in-river
155 concentrations after mixing at the point of discharge, allowing for upstream concentrations of
156 the pharmaceutical. Flow in the river and flow volume from the sewage works are described
157 as distributions. The other parameters are held constant. The river flow is characterised as
158 log-normal and the sewage works flows as normal. Changes in concentration with ‘flow time’
159 due to dilution, from e.g. inputs from tributaries, and degradation also are calculated.

160 The emissions of an API for a given STP are typically derived from prescription data and
161 STP characteristics. The STP inflow concentration (C_i) is estimated from the projected/actual
162 per capita mass of chemical used/excreted (M , $\mu\text{g}/\text{cap}/\text{day}$), and the STP dry weather flow
163 (DWF , L/day), using Equation 1:

164

$$165 \quad C_i = \frac{M \cdot P}{DWF} \quad \text{Equation 1}$$

166 Where P is the population served by the works and was obtained from the water utilities
167 operating each works for all works across England and Wales. A normal distribution is
168 assumed for DWF. The other parameters are fixed for each sewage treatment works.

169 The model allows removal in treatment efficiency to be considered using a global removal
170 rate (r) including sewer removal, primary treatment and secondary treatment. The value of r
171 can be specific to each STP modelled and can be varied according to the type of plant and
172 levels of treatment applied. The final concentration in the effluent (C_{eff}), is thus

173

$$174 \quad C_{eff} = C_i \cdot (1 - r) \quad \text{Equation 2}$$

175

176 Equations 1 and 2 describe the STP process. They are calculated in turn for each of the Monte
177 Carlo iterations, so that the point source emission is expressed as a distribution.

178 Within LF2000-WQX, the whole catchment is structured as a network of interconnected
179 model reaches. Reaches are defined as river stretches between model features, which are
180 usually defined by significant tributaries, confluence of model reaches and STPs. Within the
181 river, the model can simulate either conservative (no in-stream removal) or degradable (in-
182 stream removal) substances. Modelling a degradable determinand, the concentration
183 downstream (C_{DS}), after in-stream removal is defined with a first order exponential decay:

184

$$185 \quad C_{DS} = C_{EP} e^{-k t} \quad \text{Equation 3}$$

186

187 Where C_{EP} is the concentration in the river at the point of entry of an STP discharge, k (day^{-1})
188 is the decay rate, and t (day) is the time of travel along a reach defined as the reach length
189 divided by the velocity of the river.

190

191 1.3. *Estimation of removal of APIs using inverse modelling and comparison with removal*
192 *estimates using standard modelling approach*

193 Inverse modelling was used to estimate the mean, maximum and minimum removal of the
194 study APIs between the point of use and the point at which surface water was sampled for the
195 four study sites. Estimates of use of APIs were based on UK usage in 2009 (IMS Health,
196 2012) and were expressed as a per capita consumption per day (derived using the estimated
197 UK population of 61,126,832; Eurostat, 2012). The LF2000-WQX model was run for all of
198 the monitoring study sites, using only the per capita usage data (Table 1). It was assumed that
199 all the prescribed drugs were consumed and excreted and that there was no removal in the
200 STPs. For each API, percentage effective removals were calculated by dividing the measured
201 value for an API at each of the study sites by the predicted mean value for the specific site.

202 To allow comparison of the inverse modelling removal estimates with removal estimates
203 from the 'standard' forward approach to API exposure modelling, removal percentages were
204 also calculated for each of the monitoring study sites based on published data on metabolism,
205 removal in treatment and dissipation in surface waters (Table 3). Where a range of values
206 were reported for these input parameters, lowest and highest values were used to produce
207 'worst' and 'best' case estimates of removal. For use in broader modelling, a correction was
208 made, using dissipation data from Table 3, to the inverse modelled removal rates to account
209 for the in stream-dissipation of a study compound between the points of emission to the
210 catchments and the monitoring points.

211
212 1.4. *Evaluation of modelling approach against monitoring data*

213 To evaluate the performance of the approach, predictions of concentrations in river
214 catchments in England and Wales were compared with measured environmental
215 concentrations from a range monitoring studies that have been performed in the UK over the

216 past eleven years (Boxall *et al.*, 2012b; Hilton *et al.*, 2003; Ashton *et al.*, 2004; Thomas and
217 Hilton, 2004; Bound and Voulvoulis, 2006; Roberts and Bersuder, 2006; Roberts and
218 Thomas, 2005; Kasprzyk-Hordern *et al.*, 2007 and 2009; Kasprzyk-Hordern and Baker, 2012;
219 Zhang and Zhou, 2007; Zhou *et al.*, 2009; Table 4). Mean concentrations were then obtained
220 for each sampling point and these mean MECs were then collated into one single distribution
221 using the approach described by Straub (2008) and Metcalfe *et al.* (2008). Median and upper
222 and lower quartiles were derived for the concentration distributions. Concentrations of
223 monitored APIs were then estimated for all river reaches in the monitored catchments using
224 the mean, minimum and maximum removal rates that were derived from the inverse
225 modelling and corrected for in stream dissipation. Concentration distributions and associated
226 summary statistics from the monitoring data analyses and the modelling were then compared.

227

228 *1.5. Assessment of pharmaceutical risks to aquatic systems in England and Wales*

229 The average, maximum and minimum removal estimates and corrected for in-stream
230 dissipation data were then used in the LF2000-WQX model to predict concentrations of the
231 12 study APIs in 3117 river reaches distributed across 22 large catchments in England and
232 Wales serving a population of 21 million people. Annual mean predicted environmental
233 concentrations (PECs) were obtained for each pharmaceutical for every reach in each
234 catchment.

235 To assess the implications of the predicted exposure distributions in terms of ecological risks,
236 data on the acute and chronic (growth and reproduction) toxicity of the study APIs to algae,
237 invertebrates and fish were extracted from the literature (Table 5). With the exception of
238 naproxen, these data were used to derive predicted no-effect concentrations (PNECs) for each
239 study pharmaceutical using assessment factors recommended by the European Chemicals
240 Agency (ECHA, 2010). Studies reporting non-regulatory endpoints (e.g. biomarker,

241 histological and behavioural responses) were not considered in the derivation of PNECs. For
242 naproxen, the Environmental Reference Concentration (ERC) proposed by Murray-Smith *et*
243 *al* (2012) was used. Risk characterisation ratios (RCRs) were then calculated for each river
244 reach using equation 4.

245

$$246 \quad RCR = \frac{PEC}{PNEC \text{ or } ERC} \quad \text{Equation 4}$$

247

248 Estimated RCRs for all the reaches in all the 22 catchments were then combined in order to
249 develop risk distributions for each pharmaceutical. An $RCR \geq 1$ was considered as indicative
250 of an unacceptable risk posed by an API to the aquatic population in a reach. In the past,
251 diclofenac has been identified as a potential priority substance under the European Water
252 Framework Directive and an environmental quality standard (EQS) of 0.1 $\mu\text{g/l}$ was proposed
253 for this API. Therefore, in addition to deriving RCR distributions for diclofenac, we also
254 compared exposure predictions to the proposed EQS value to see what the implication of the
255 EQS would have been had it been introduced.

256

257 **2. Results**

258 *2.1. Comparison of removal using forward with removal based on monitoring data at the* 259 *study sites*

260 Mean inverse modelling-based estimates of removal between the point of prescription/sale
261 and the point of monitoring into the surface waters for the monitoring study sites ranged from
262 90.63 (carbamazepine) to 99.86% (ibuprofen) (Table 6). Concentrations of cyclophosphamide,
263 fluoxetine, ketoprofen, orlistat and simvastatin were below detection limits in the monitoring
264 study, so it was only possible to estimate a minimum removal rate for these substances –
265 these were all greater than 95.5% (Table 6). In comparison, estimates of effective removal,

266 based on forward modelling using data on usage, metabolism and dissipation in wastewater
267 treatment and surface waters resulted in 'worst' case estimates of between 4 (atenolol) and
268 97.1% (naproxen) and 'best' case estimates of between 70.2 (trimethoprim) and 99.8%
269 (ibuprofen) removal between use by the patient and the sampling points for the four study
270 sites (Table 6). Mean percentage removal values for carbamazepine, diclofenac, fluoxetine,
271 furosemide and trimethoprim, obtained from usage, metabolism and wastewater and surface
272 water dissipation data were lower than removal values obtained using inverse modelling of
273 the monitoring data and for selected compounds (e.g. trimethoprim), there was a large
274 difference between the two approaches. Due to a lack of data, it was not possible to estimate
275 removal percentages for cyclophosphamide, ketoprofen, orlistat and simvastatin using the
276 forward modelling approach.

277 Correction of the inverse modelling data for in-stream dissipation of the study compounds
278 indicated that on average between 90.01 (atenolol) and 99.84% (ibuprofen) is removed
279 between the point of prescription/use and the points of emission from treatment plants within
280 the monitoring study catchments (Table 6). With the exception of atenolol where on average
281 3% of the compound was estimated to have dissipated in the rivers within the catchment, in-
282 stream dissipation was found to actually play a negligible role in the overall dissipation of the
283 study compounds and the monitoring sites. Never-the-less, the corrected values were
284 employed in the subsequent landscape scale exposure modelling.

285

286 *2.2. Comparison of exposure predictions against monitoring data*

287 It was possible to obtain good datasets on mean concentrations of atenolol, carbamazepine,
288 diclofenac, ibuprofen and trimethoprim in surface waters at different points within 10
289 catchments allowing concentration distributions to be derived (Figure 1). Mean, minimum
290 and maximum estimated removal rates between the point of use and emission to surface

291 waters were used in the LF2000-WQX model to estimate mean concentrations of the study
292 compounds for every river reach in the 10 monitored catchments in England and Wales.
293 Summary statistics for the distributions of mean predicted concentrations for all river reaches
294 in the monitored catchments, obtained from the modelling, are shown in Table 7. With the
295 exception of ibuprofen, there was good agreement between the monitored and modelled
296 distributions (Table 7; Figure 1). For ibuprofen, the modelled median concentrations and
297 upper and lower quartiles for the distributions were substantially smaller than the summary
298 statistic values obtained from monitoring studies.

299

300 *2.3. Assessment of risks of APIs to surface waters in England and Wales*

301 To assess the implications of the distributions of concentrations of the APIs, concentrations
302 were used alongside ecotoxicity data to characterise the level of risk posed by each API in
303 each of the river reaches modelled. Risk characterisation ratios for the study APIs for the 22
304 catchments (Figure 2) show that, for trimethoprim, furosemide, diclofenac and atenolol,
305 RCRs were 0.008 or lower, indicating that these substances pose a very low risk to aquatic
306 systems in England and Wales (Figure 2A). While the maximum RCRs of greater than one
307 were obtained for carbamazepine, fluoxetine and simvastatin in one of the 3312 river reaches
308 and for orlistat in 12 river reaches, simvastatin exceeded one, in the vast majority of reaches a
309 RCRs were lower than one indicating that these substances generally pose an acceptable risk
310 to the aquatic environment. For orlistat, simvastatin and fluoxetine, exposure estimates are
311 based on limits of detection so in reality RCRs will be lower still. However, the maximum
312 RCR for ibuprofen was 174 and, for this compound, 49.5% of river reaches across the 22
313 catchments were predicted to be at risk. When the catchments were considered individually
314 (Figure 2B), nine of the catchments were found to have median concentrations for ibuprofen
315 greater than the PNEC. The proposed EQS for diclofenac is 320-times lower than the

316 calculated PNEC. Comparison of this value with the exposure data suggested that 4.5% of
317 river reaches in the 22 catchments would have concentrations higher than the proposed
318 standard (Figure 2A), while none would have a concentration higher than the PNEC.

319

320 **3. Discussion**

321 A number of studies over the past few years have applied modelling approaches to predict the
322 occurrence and risks of APIs in surface waters in different regions of the world (Williams *et*
323 *al.*, 2009; Hannah *et al.*, 2009; Letzel *et al.*, 2009). Typically, the modelling uses information
324 on the usage of an API in an area, metabolism, fate in wastewater treatment systems and fate
325 in receiving waters to estimate surface water concentrations. Comparison of estimates of
326 removal, obtained using these information, with estimates of total removal, obtained using
327 inverse modelling based on monitoring data for the four study sites, indicates that the
328 standard modelling approach can either over- or under-estimate removal of pharmaceuticals
329 in the real environment. This is probably one reason why previous studies have often shown
330 little correlation between measured and modelled data (e.g. Metcalfe *et al.* 2008). The
331 mismatch between the inverse modelled removal rates and rates obtained from usage,
332 metabolism and dissipation data are likely explained by a number of factors, including: not
333 all of a prescribed API is released to the wastewater system; metabolism in the actual
334 population is greater or lower than indicated by literature studies on a few individuals; and
335 variability in the types and performance of wastewater treatment works. When ranges of
336 values are available for a particular model input parameter, there were also large differences
337 between the maximum and minimum removal percentages for some compounds. This was
338 particularly true for atenolol and furosemide, where removal was estimated to range from 4.0
339 to 97.9% and from 10 to 77.5%, respectively, highlighting the difficulty in selecting model
340 input data. Smaller variation was seen for the inverse-modelling derived total removal rates

341 across the four study sites. Differences in demographic characteristics and the treatment
342 technologies across the sites may contribute to the differences between the forward and
343 inverse modelling derived values across the sites.

344 For six of the seven study compounds, where extensive datasets were available on
345 concentrations in rivers in England and Wales, there was close agreement between the results
346 of the exposure modelling and the monitoring data. The disagreement between modelled and
347 measured distribution statistics for ibuprofen may be partly explained by the fact that the
348 ibuprofen monitoring dataset was dominated by measurements made in 2003 during periods
349 of low precipitation when dilution of effluent through the wastewater treatment plants and
350 dilution by receiving waters would be small. In addition, IMS Health data indicate that usage
351 of ibuprofen in 2003 was higher than in 2009 when our study was performed (i.e. 293,802 kg
352 in 2003 compared with 277,465 kg in 2009). There have also been significant advances in
353 analytical methodologies since 2003, which have reduced the occurrence of analytical
354 artefacts such as matrix interferences. In a recent large-scale monitoring study involving
355 analysis of around 8,000 samples of undiluted wastewater effluents at over 160 treatment
356 works, median concentrations for ibuprofen have been reported to be 330 ng/l (95 percentile
357 concentration = 2.48 $\mu\text{g l}^{-1}$) suggesting the monitoring data from the earlier study are likely
358 not typical of concentrations across the broader landscape (UKWIR, 2012). The inverse
359 model results better reflect the much smaller values measured for ibuprofen in the most
360 recent monitoring studies performed in 2006, 2007 and 2009.

361 PNECs were derived from available acute and chronic ecotoxicity studies using standard
362 endpoints such as mortality, reproduction and growth and assessment factors recommended
363 by ECHA. Numerous studies have also explored effects of APIs on non-standard endpoints
364 such as behaviour, histology and biochemical effects, sometimes at concentrations much
365 lower than the standard endpoints (Hoeger *et al.*, 2005; Ankley *et al.*, 2007; Stanley *et al.*,

366 2007; Boxall *et al.*, 2012b). However, in this study we did not use these data to inform the
367 PNEC derivation. This approach is consistent with the recent Technical Guidance Document
368 for deriving Environmental Quality Standard (EQSs) in the scope of the European Water
369 Framework Directive (EQS-TGD, 2011). With the exception of diclofenac, these non-
370 standard effects are seen at concentrations higher than the estimated PNECs, providing re-
371 assurance that the PNEC values for most of the study substances are protective against more
372 subtle effects. For diclofenac, the EQS value is slightly higher than concentrations where
373 histological and biochemical effects have been reported. A recent study (Memmert *et al.*,
374 2103) has questioned the reliability of the conclusions on the histopathology studies on which
375 the EQS is based and it is possible that the EQS is overly conservative.

376 With the exception of ibuprofen, where a risk was identified for 49.5% of river reaches,
377 RCRs for the other study compounds in river reaches in England and Wales were generally
378 lower than one (for carbamazepine, orlisat, fluoxetine and simvastatin a risk was identified in
379 one, one and 12 of the 3312 river reaches respectively), indicating that the other compounds
380 pose an acceptable risk to the UK environment. The findings for ibuprofen agree with
381 conclusions from other studies into the risks of APIs in aquatic systems, where ibuprofen has
382 been highlighted as a drug of potential concern in river systems (Christensen *et al.*, 2009;
383 Lienert *et al.*, 2007). We would therefore advocate that further work is carried out to explore
384 the wider occurrence of ibuprofen in surface waters in England and Wales and to explore
385 whether effects are occurring in the catchments where a significant proportion of river
386 reaches are predicted to be at risk; the PNEC may also need to be re-assessed as well.

387 Comparison of exposure predictions for diclofenac with the previously proposed EQS for
388 diclofenac, indicated that 4.5% of river reaches would have exceeded the EQS had it been
389 adopted. This percentage is in agreement with the value of 3-5% previously predicted for

390 EQS exceedences in rivers in England using the forward modelling approach (Johnson *et al.*,
391 2013).

392 Overall, this study demonstrates the potential of using inverse modelling alongside
393 monitoring data to generate model input data in exposure and risk assessment. As a total
394 removal rate is estimated for a broad scale, the approach offers a number of advantages, i.e. it
395 takes into account factors such as the non-use of prescribed drugs by patients; it addresses
396 differences in metabolism across the population; it accounts for dissipation processes in the
397 local sewerage network and it accounts for differences in effectiveness of different
398 wastewater treatment technologies in a catchment. The four study sites used in this study
399 were based in four different counties located in the South East and Midland regions of
400 England so the approach appears to be effective at estimating exposure for different regions
401 in a country the size of England. This is backed up by the comparisons of exposure
402 predictions for the catchments that have been monitored in England and Wales with the
403 experimentally-derived data.

404 The approach is, however, reliant on the availability of good quality monitoring data and
405 cannot be applied to compounds that are not yet in use. Cultural and demographic differences
406 might mean that the total removal predictions from this study cannot be applied to other
407 countries. However, there is no reason why a similar monitoring and modelling strategy to
408 that employed in the current study could not be applied elsewhere in order to generate state-
409 or country-specific removal rates and hence assess the broad scale exposure risks of APIs in
410 other regions of the world. The concept could also be applied at different stages in the
411 pathway of a pharmaceutical from the patient to environmental receptors to better understand
412 key dissipation processes for pharmaceuticals to inform future modelling initiatives.

413

414 **Acknowledgements**

415 We are grateful to the Drinking Water Inspectorate for funding the monitoring component of
416 this work. Many thanks to Mathieu Guillaume (F. Hoffmann-La Roche, Basle) for help with
417 the IMS Health data. IMS Health is acknowledged for the use of API sales data; however,
418 analysis of IMS Health data was arrived at independently by the authors of the present paper
419 on the basis of the data and other information and IMS Health is not responsible for any
420 reliance by recipients of the data or any analysis thereof. We are grateful to an anonymous
421 reviewer who provided constructive comments on an earlier version of this manuscript.

422

423 **References**

- 424 Anderson PD, D'Aco VJ, Shanahan P, Chapra SC, Buzby ME, Cunningham VL, et al.
425 Screening analysis of human pharmaceutical compounds in US surface waters.
426 *Environmental Science and Technology* 2004; 38: 838–849.
- 427 Ando T, Nagase H, Eguchi K, Hirooka T, Nakamura T, Miyamoto K, et al. A novel method
428 using cyanobacteria for ecotoxicity test of veterinary antimicrobial agents. *Environ Toxicol*
429 *Chem* 2007; 26(4): 601–606.
- 430 Andreozzi R, Raffaele M, Paxeus N. Pharmaceuticals in STP effluents and their solar
431 photodegradation in aquatic environment. *Chemosphere* 2003; 50: 3019-3030.
- 432 Ankley GT; Brooks BW; Huggett DB; Sumpter JP. Repeating history: Pharmaceuticals in
433 the environment. *Environ. Sci. Technol.* 2007; 41: 8211-8217.
- 434 Araujo L, Villa N, Camargo N, Bustos M, Garcia T, de Jesus Prieto A. Persistence of
435 gemfibrozil, naproxen and mefenamic acid in natural waters. *Environ. Chem. Lett.* 2011;
436 9:13-18.
- 437 Ashton D, Hilton M, Thomas KV. Investigating the environmental transport of human
438 pharmaceuticals to streams in the United Kingdom. *Sci. Tot. Environ.* 2004; 333, 167–184.

439 Bagley CM, Bostick FW, DeVita VT. Clinical pharmacology of cyclophosphamide. *Cancer*
440 *Res.* 1973; 33, 226-233.

441 Bound JP, Voulvoulis N. Predicted and measured concentrations for selected pharmaceuticals
442 in UK rivers: Implications for risk assessment. *Water Res.* 2006; 40, 2885–2892.

443 Boxall ABA. The environmental side effects of medication. *EMBO Reports.* 2004; 5(12),
444 1110-1116.

445 Boxall ABA, Fogg LA, Kay P, Blackwell PA, Pemberton EJ, Croxford A. Veterinary
446 medicines in the environment. *Reviews in Environmental Contamination and Toxicology.*
447 2004; 180: 1-91.

448 Boxall ABA, Rudd MA, Brooks BW, Caldwell DJ, Choi K, Hickmann S. Pharmaceuticals
449 and personal care products in the environment: What are the key questions. *Environ. Health*
450 *Persp.* 2012a; 120(9):1221-1229.

451 Boxall ABA, Monteiro SC, Fussell R, Williams RJ, Bruemer J, Greenwood R, et al. *Targeted*
452 *Monitoring for Human Pharmaceuticals in Vulnerable Source and Final Waters.* Department
453 for Environment, Food and Rural Affairs, London, England 2012b.

454 Breton R, Boxall ABA. Pharmaceuticals and personal care products in the environment:
455 regulatory drivers and research needs. *QSAR Comb. Sci.* 2003; 22, 399-409.

456 Brooks BW, Richards SM, Weston J, Turner PK, Stanley JK, La Point TW, et al. Aquatic
457 ecotoxicology of fluoxetine: a review of recent research. In: Dietrich D., Webb S., Petry T.,
458 Eds. Hot spot pollutants: pharmaceuticals in the environment. Academic/Elsevier, New York,
459 USA, 2005.

460 Brun GL, Bernier M, Losier R, Doe K, Jackman P, Lee H-B. Pharmaceutically active
461 compounds in Atlantic Canadian sewage treatment plant effluents and receiving waters, and
462 potential for environmental effects as measured by acute and chronic toxicity. *Environ.*
463 *Toxicol. Chem.* 2006; 25(8): 2163-2176.

464 Bürge IJ, Poiger T, Müller MD, Buser H-R. Caffeine, an anthropogenic marker for
465 wastewater contamination of surface waters. *Environmental Science and Technology* 2003;
466 37: 691–700.

467 Buser H-R, Poiger T, Müller MD. Occurrence and environmental behaviour of the chiral
468 pharmaceutical drug ibuprofen in surface waters and in wastewater. *Environmental Science*
469 *and Technology* 1999; 33: 2529–2535.

470 Christensen AM, Markussen B, Baun A. Halling-Sorensen, B. Probabilistic environmental
471 risk characterization of pharmaceuticals in sewage treatment plant discharges. *Chemosphere*
472 2009; 77(3): 351-358.

473 Cleuvers M. Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen,
474 and acetylsalicylic acid. *Ecotox. Environ. Safe.* 2004; 59: 309–315.

475 Daughton C, Ternes T. Pharmaceuticals and personal care products in the environment:
476 agents of subtle change? *Environ. Health Persp.* 1999; 107: 907–937.

477 De Lorenzo ME, Fleming J. Individual and mixture effects of selected pharmaceuticals and
478 personal care products on the marine phytoplankton species *Dunaliella tertiolecta*. *Arch.*
479 *Environ. Contam. Toxicol.* 2008; 54:203–210

480 Dorne JLCM. Metabolism, variability and risk assessment. *Toxicology* 2010; 268, 156-164.

481 ECHA. *Guidance on information requirements and chemical safety assessment. Chapter*
482 *R.10: Characterisation of dose [concentration]-response for environment*. ECHA, Helsinki,
483 Finland, 2010.

484 EMA. *Guideline on the environmental risk assessment of medicinal products for human use*.
485 European Medicines Agency, London, U.K., 2006.

486 Environment Agency. *Development of the integrated water resources and water quality*
487 *modelling system*. Environment Agency, Bristol, England, 2004.

488 EQS-TGD, *Common Implementation Strategy for the Water Framework Directive*
489 *(2000/60/EC). Technical guidance for deriving environmental quality standards: Guidance*
490 *Document No. 27*. European Commission, Brussels, 2011.

491 Eurostat. *Population in Europe*. European Union Statistics Office, Brussels, 2012.

492 Ferrari B, Mons R, Vollat B, Fraysse B, Paxeus N, Lo Giudice R. et al. Environmental risk
493 assessment of six human pharmaceuticals: are the current environmental risk assessment
494 procedures sufficient for the protection of the aquatic environment? *Environ. Toxicol. Chem.*
495 2009; 23(5): 1344-1354.

496 Ferrari B, Paxeeus N, Lo Giudice R, Pollio A, Garric J. Ecotoxicological impact of
497 pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibrac acid, and
498 diclofenac. *Ecotox. Environ. Safety* 2003; 55: 359-370.

499 Fono LJ, Kolodziej EP, Sedlak DL. Attenuation of wastewater-derived contaminants in an
500 effluent-dominated river. *Environ. Sci. Technol.* 2006; 40, 7257-7262.

501 Garcia-Ac A, Segura PA, Gagnon C, Sauvé S. Determination of bezafibrate, methotrexate,
502 cyclophosphamide, orlistat and enalapril in waste and surface wtaers using on-line solid-
503 phase extraction liquid chromatography coupled to polarity-switching electrospray tandem
504 mass spectrometry. *Journal of Environmental Monitoring* 2009; 11: 830–838.

505 Gros M, Petrovič M, Ginebreda A, Barceló D. Removal pf pharmaceuticals during
506 wastewater treatment and environmental risk assessment using hazard indexes. *Environ Int*
507 2010; 36: 15–26.

508 GSK. *Safety datasheet: Alli*. GSK, Brentford, Middlesex, UK, 2008.

509 Han S, Choi K, Kim J, Ji K, Kim S, Ahn B, et al. Endocrine disruption and consequences of
510 chronic exposure to ibuprofen in Japanese medaka (*Oryzias latipes*) and freshwater
511 cladocerans *Daphnia magna* and *Moina macrocopa*. *Aquat. Toxicol.* 2010; 98: 256-264.

512 Hannah R, D'Aco VJ, Anderson PD, Buzby ME, Caldwell DJ, Cunningham VL. Exposure
513 assessment of 17 α -ethinylestradiol in surface waters of the United States and Europe.
514 *Environ. Toxicol. Chem.* 2009; 28(12), 2725-2732.

515 Heberer, T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic
516 environment: a review of recent research data. *Toxicology Letters* 2002; 131: 5–17.

517 Heberer, T.; Reddersen, K.; Mechlinski, A. From municipal sewage to drinking water: fate
518 and removal of pharmaceutical residues in the aquatic environment in urban areas. *Wat. Sci.*
519 *Technol.* 2002; 46(3), 81–88.

520 Hilton, M.J.; Thomas, K.V.; Ashton, D. *Targeted Monitoring Programme for*
521 *Pharmaceuticals in the Aquatic Environment*. Environment Agency, Bristol, England, 2003.

522 Hirsch, R.; Ternes, T.; Heberer, K.; Kratz, K. Occurrence of antibiotics in the aquatic
523 environment. *Sci. Total Environ.* 1999; 225, 109-118.

524 Hoeger, B.; Kollner, B.; Dietrich, D.R.; Hitzfeld, B. Water-borne diclofenac affects kidney
525 and gill integrity and selected immune parameters in brown trout (*Salmo trutta f. fario*).
526 *Aquat. Toxicol.* 2005; 75, 53-64.

527 IMS Health. *Global Product Strategy; IMS MIDAS in PADDs. Subscription database*. IMS
528 Health Ltd, Danbury, USA, 2012.

529 Isidori M, Lavorgna M, Nardelli A, Parrella A, Previtera L, Rubino M. Ecotoxicity of
530 naproxen and its phototransformation products. *Sci. Tot. Environ.* 2005; 348: 93-101.

531 Janna H, Scrimshaw MD, Williams RJ, Churchley J, Sumpter JP. From dishwasher to tap?
532 Xenobiotic substances benzotriazole and tolyltriazole in the environment. *Environ. Sci.*
533 *Technol.* 2011; 45(9): 3858-3864.

534 Johnson AC, Dumont E, Williams RJ, Oldenkamp R, Cisowska I, Sumpter JP. Do
535 Concentrations of Ethinylestradiol, Estradiol, and Diclofenac in European Rivers Exceed

536 Proposed EU Environmental Quality Standards? *Environ. Sci. Technol.* 2013; 47(21): 12297-
537 304.

538 Kasprzyk-Hordern B, Baker DR. Enantiomeric profiling of chiral drugs in wastewater and
539 receiving waters. *Environ. Sci. Technol.* 2012, 46; 1681–1691.

540 Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. Multi-residue method for the determination of
541 basic/neutral pharmaceuticals and illicit drugs in surface water by solid-phase extraction and
542 ultra performance liquid chromatography–positive electrospray ionisation tandem mass
543 spectrometry. *J. Chromat. A.* 2007; 1161, 132–145.

544 Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. The removal of pharmaceuticals, personal
545 care products, endocrine disruptors and illicit drugs during wastewater treatment and its
546 impact on the quality of receiving waters. *Water Res.* 2009; 43, 363–380.

547 Key PB, Hoguet J, Chung KW, Venturell JJ, Pennington PL, Fulton MH. Lethal and
548 sublethal effects of simvastatin, irgarol, and PBDE-47 on the estuarine fish, *Fundulus*
549 *heteroclitus*. *J. Environ. Sci. Hlth. B.* 2009; 44(4): 379-382.

550 Kim Y, Choi K, Jung J, Park S, Kim P-G, Park J. Aquatic toxicity of acetaminophen,
551 carbamazepine, cimetidine, diltiazem and six major sulfonamides, and their potential
552 ecological risks in Korea. *Environment International* 2007; 33: 370–375

553 Kolpin D, Furlong E, Meyer M, Zaugg S, Barber L, Buxton H. Pharmaceuticals, hormones,
554 and other organic wastewater contaminants in US streams, 1999 – 2000: A national
555 reconnaissance. *Environ. Sci. Technol.* 2002; 32, 1202 - 1211.

556 Küster A, Alder AC, Escher BI, Duis K, Fenner K, Garric J. et al. Environmental Risk
557 Assessment of Human Pharmaceuticals in the European Union: A Case Study with the β -
558 Blocker Atenolol. *Integrated Environmental Assessment and Management* 2010; 6(suppl 1):
559 514–523

560 Kwon J-W, Armbrust K. Laboratory persistence and fate of fluoxetine in aquatic
561 environments. *Environ. Toxicol. Chem.* 2006; 25(10): 2561-2568.

562 Lam MW, Young CJ, Brain RA, Johnson DJ, Hanson MA, Wilson CJ. Aquatic persistence of
563 eight pharmaceuticals in a microcosm study. *Environ. Toxicol. Chem.* 2004; 23(6): 1431–
564 1440.

565 Leclercq M, Mathieu O, Gomez E, Casellas C, Fenet H, Hillaire-Buys D. Presence and fate
566 of carbamazepine, oxcarbazepine, and seven of their Metabolites at wastewater treatment
567 plants. *Archives of Environmental Contamination and Toxicology* 2009; 56: 408-415.

568 Lee H-B, Peart TE, Svoboda ML, Backus S. Occurrence and fate of rosuvastatin, rosuvastatin
569 lactone, and atorvastatin in Canadian sewage and surface water samples. *Chemosphere* 2009;
570 77: 1285-1291.

571 Letzel M, Metzner G, Letzel T. Exposure assessment of the pharmaceutical diclofenac based
572 on long-term measurements of the aquatic input. *Environ. Internat.* 2009; 35, 363-368.

573 Lienert J, Güdel K, Escher BI. Screening Method for Ecotoxicological hazard assessment of
574 42 pharmaceuticals considering human metabolism and excretory Routes. *Environ. Sci.*
575 *Technol.* 2007; 41, 4471–4478.

576 Lister A, Regan C, Van Zwol J, Van Der Kraak GJ. Inhibition of egg production in zebrafish
577 by fluoxetine and municipal effluents: a mechanistic perspective. *Aquat Toxicol* 2009; 95:
578 320–329.

579 Memmert U, Peither A, Burri R, Weber K, Schmidt T, Sumpter JP, Hartmann A. Diclofenac:
580 new data on chronic toxicity and bioconcentration in fish. *Environ. Toxicol. Chem.* 2013; 32:
581 442-452.

582 Metcalfe CD. et al. Exposure assessment methods for veterinary and human-use medicines
583 in the environment: PEC vs MEC comparisons. In *Pharmaceuticals in the Environment, 2nd*
584 *Edition*; Kümmerer K Ed.; Springer, Berlin Heidelberg, Germany, 2008.

585 Monteiro SC, Boxall ABA. Occurrence and fate of human pharmaceuticals in the
586 environment. *Rev. Environ. Contam. T.* 2010; 202, 53-154.

587 Murray-Smith RJ, Coombe VT, Grönlund MH, Waern F, Baird JA. Managing emissions of
588 active pharmaceutical ingredients from manufacturing facilities: An environmental quality
589 standard approach. *Integr. Environ. Assess. Man.* 2012; 8(2), 320-330

590 Musson SE, Townsend TG. Pharmaceutical compound content of municipal solid waste
591 pharmaceutical compound content of municipal solid waste. *J. Haz. Mater.* 2009; 162, 730–
592 735

593 Nalecz-Jawecki G.: Evaluation of the in vitro biotransformation of fluoxetine with HPLC,
594 mass spectrometry and ecotoxicological tests. *Chemosphere* 2007; 70: 29–35.

595 Oakes KD, Coors A, Escher BI, Fenner K, Garric J, Gust M. Environmental risk assessment
596 for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk
597 assessment framework. *IEAM* 2010; 6(1): 524-539.

598 Ort C, Hollender J, Schaerer M, Model-Based Evaluation of Reduction Strategies for
599 Micropollutants from Wastewater Treatment Plants in Complex River Networks,
600 *Environmental Science Technology* 2009; 43(9), 3214-3220.

601 Paffoni C, Welte B, Gousailles M, Montiel A. Nouvellem molécules mises en cause par les
602 directives européennes: de la station d'épuration à l'usine de traitement d'eau potable.
603 *European Journal of Water Quality* 2006; 37(1): 21–38.

604 Park S, Choi K. Hazard assessment of commonly used agricultural antibiotics on aquatic
605 ecosystems. *Ecotoxicology* 2008; 17: 526–538.

606 Paxéus N. Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs),
607 gemfibrozil, carbamazepine, β -blockers, trimethoprim and triclosan in conventional
608 wastewater treatment plants in five EU countries and their discharge to the aquatic
609 environment. *Water Science and Technology* 2004; 50(5): 253-260.

610 Piecha M, Sarakha M, Trebse P, Kocar D. Stability studies of cholesterol lowering statin
611 drugs in aqueous samples using HPLC and LC–MS. *Environ. Chem. Lett.* 2010; 8:185-191.

612 Pistocchi A, Marinov D, Pontes S, Gawlik BM. Continental scale inverse modeling of
613 common organic water contaminants in European Rivers. *Environ. Poll.* 2012; 162, 159-167.

614 Price O.R, Williams RJ, van Egmond R, Wilkinson MJ, Whelan MJ. Predicting accurate and
615 ecologically relevant regional scale concentrations of triclosan in rivers for use in higher-tier
616 aquatic risk assessments. *Environ. Internat.* 2010; 36, 521-526.

617 Price OR, Williams RJ, Zhang Z, van Egmond R. Modelling concentrations of
618 decamethylcyclopentasiloxane in two uk rivers using lf2000-wqx. *Environ. Pollut.* 2010;
619 158(2), 356-360.

620 Roberts PH, Bersuder P. Analysis of OSPAR priority pharmaceuticals using high-
621 performance liquid chromatography-electrospray ionisation tandem mass spectrometry. *J.*
622 *Chromat. A.* 2006; 1143, 143–150.

623 Roberts PH, Thomas KV. The occurrence of selected pharmaceuticals in wastewater effluent
624 and surface waters of the lower Tyne catchment. *Sci. Tot. Environ.* 2005; 356, 143–153.

625 Rowney NC, Johnson AC, Williams RJ. Cytotoxic drugs in drinking water: A prediction and
626 risk assessment exercise for the thames catchment in the united kingdom. *Environ. Toxicol.*
627 *Chem.* 2009; 28(12), 2733-2743.

628 Runkel R, Chaplin M, Boost G, Segre E, Forchielli E. Absorption, distribution, metabolism
629 and excretion of naproxen in variouslaboratory animals and human subjects. *J. Pharm. Sci.*,
630 1972; 61, 703-708.

631 SCHER. Opinion on ‘Chemicals and the water framework directive: draft environmental
632 quality standards’ Diclofenac.SCHER, Brussels, Belgium, 2011.

633 Schowanek D, Webb S. Exposure simulation for pharmaceuticals in European surface waters
634 with GREAT-ER. *Toxicol. Lett.* 2002; 131, 39–50

635 Schwab BW, Hayes EP, Fioric JM, Mastrocco FJ, Roden NM, Cragin D. Human
636 pharmaceuticals in US surface waters: A human health risk assessment. *Regulat. Toxicol.*
637 *Pharmacol.* 2005; 42(3), 296-312.

638 Seehusen DA, Edwards J. Patient practices and beliefs concerning disposal of medications. *J.*
639 *Am. Board. Fam. Med.* 2006; 19, 542-7.

640 SFT. Initial assessment of eleven pharmaceuticals using the EMEA guideline in Norway.
641 Statens forurensningstilsyn (SFT), Strømsveien, Norway, 2006.

642 Sipma J, Osuna B, Collado N, Monclús H, Ferrero G, Comas J. Comparison of removal of
643 pharmaceuticals in MBR and activated sludge systems. *Desalination* 2010; 250, 653-659.

644 Stanley JK, Ramirez AJ, Chambliss CK, Brooks BW. Enantiospecific sublethal effects of the
645 antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. *Chemosphere* 2007;
646 69(1), 9-16.

647 Straub JO, Stewart KM. Deterministic and probabilistic acute-based environmental risk
648 assessment for naproxen for western Europe. *Environ. Toxicol. Chem.* 2007; 26(4):795-806.

649 Straub JO. Deterministic and probabilistic environmental risk assessment for diazepam. In
650 *Pharmaceuticals in the Environment; Sources, Fate, Effects and Risks*; Kümmerer K, ed.
651 Springer, Heidelberg, Germany, 2008.

652 Ternes T, Bonerz M, Schmidt T. Determination of neutral pharmaceuticals in wastewaters
653 and rivers by LC-ES-tandem MS. *Journal of Chromatography A* 2001; 938: 175-185.

654 Thomas KV, Hilton MJ. The occurrence of selected human pharmaceutical compounds in
655 UK estuaries. *Mar. Pollut. Bull.* 2004; 49, 436-444.

656 Upton RA, Buskin JN, Williams RL, Holford NH, Riegelman S. Negligible excretion of
657 unchanged ketoprofen, naproxen, and probenecid in urine. *J. Pharm. Sci.* 1980; 69(11):1254-
658 7.

659 Warn AE, Brew JS. Mass balance. *Wat. Res.* 1980; 14(10), 1427-1434.

660 Williams RJ, Keller VDJ, Johnson AC, Young AR, Holmes MGR, Wells C. A national risk
661 assessment for intersex in fish arising from steroid estrogens. *Environ. Toxicol. Chem.* 2009;
662 28(1), 220-230.

663 Winter MJ, Lillicrap AD, Caunter JE, Schaffner C, Alder AC, Ramil M. Defining the chronic
664 impacts of atenolol on embryolarval development and reproduction in the fathead minnow
665 (*Pimephales promelas*). *Aquatic Toxicology* 2008; 86: 361–369.

666 Wu Y, Chen D-H, Kookana R. Aqueous photodegradation of selected antibiotics under
667 different conditions. *Energy Procedia* 2011; 11: 2098–2103.

668 Yamamoto H, Nakamura Y, Moriguchi S, Nakamura Y, Honda Y, Tamura I. Persistence and
669 partitioning of eight selected pharmaceuticals in the aquatic environment: Laboratory
670 photolysis, biodegradation, and sorption experiments. *Water Research* 2009; 43: 351-362.

671 Yang L-H, Ying G-G, Su H-C, Strauber JL, Adams MS, Binet MT. Growth-inhibiting effects
672 of 12 antibacterial agents and their mixtures on the freshwater microalga *Pseudokirchneriella*
673 *subcapitata*. *Environ Toxicol Chem* 2008; 27(5): 1201–1208.

674 Young AR, Grew R, Holmes MGR. Low flows 2000: A national water resources assessment
675 and decision support tool. *Wat. Sci. Technol.* 2003; 48(10), 119-126.

676 Zhang ZL, Zhou JL. Simultaneous determination of various pharmaceutical compounds in
677 water by solid-phase extraction–liquid chromatography–tandem mass spectrometry. *J.*
678 *Chromat. A.* 2007; 1154, 205–213.

679 Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of
680 orlistat, a lipase inhibitor, in healthy human volunteers. *J. Clinical Pharmacology* 1995;
681 35:1103-1108.

682 Zhou JL, Zhang ZL, Banks E, Grover D, Jiang JQ. Pharmaceutical residues in wastewater
683 treatment works effluents and their impact on receiving river water. *J. Haz. Mater.* 2009;
684 166, 655–661.

685 Zoukova R, Odradka P, Dolezalova L, Hilscherova K, Marsalek B, Blaha L. Ecotoxicity and
686 genotoxicity assessment of cytostatic pharmaceuticals. *Environ. Toxicol. Chem.* 2007; 26(10):
687 2208-2214.

688 Zuccato E et al. Environmental loads and detection of pharmaceuticals in Italy. In Kümmerer
689 K, (ed) *Pharmaceuticals in the Environment*. Springer, Berlin, 2001.

690 Zuccato E, Castiglioni S, Tettamanti M, Olandese R, Bagnati R, Melis M. et al. Changes
691 in illicit drug consumption patterns in 2009 detected by wastewater analysis. *Drug Alcohol*
692 *Dependence* 2011; 118(2-3), 464-469.

693

694

695

Table Legends

Table 1. Usage and mean concentrations (expressed in ng l^{-1}) measured at the four study sites. Values in parentheses for the study sites indicate the measured concentration range over the 12 month study period (Measured data taken from Boxall *et al*, 2012a).

Table 2. Characteristics of study catchments in terms of population served, types of sewage treatment plants present and average residence time between discharge points and the monitoring points.

Table 3. Information on percentage of API excreted, percentage API removed in wastewater treatment removal rates, and half lives for in stream dissipation used in the modelling of the study APIs.

Table 4. Summary of the monitoring studies used in the evaluation of the modelling approach.

Table 5. Ecotoxicological data used alongside the model predictions to establish the level of risk of the study compounds across the 18 study catchments in England and Wales.

Table 6. Summary of removal percentages for the 12 study APIs at the monitoring sites, obtained using the inverse modelling approach and the traditional forward modelling approach.

Table 7. Comparison of summary statistics for modelled and measured distributions of mean concentrations of APIs for river reaches in catchments that have been monitored for APIs in England and Wales.

Figure legends

Figure 1. Cumulative distributions of mean concentrations of pharmaceuticals in river reaches in catchments in England and Wales derived from the LF2000-WQX model or from

monitoring data. Modelled distributions are developed for the catchments where a pharmaceutical has been monitored and are based on mean, maximum and minimum inverse-modelled rates of removal. Monitoring data were taken from: Hilton *et al.*, 2003; Ashton *et al.*, 2004; Thomas and Hilton, 2004; Bound and Voulvoulis, 2006; Roberts and Bersuder, 2006; Roberts and Thomas, 2006; Kasprzyk-Hordern *et al.*, 2007, 2009, 2012; Zhang and Zhou, 2007; Zhou *et al.*, 2009; Boxall *et al.*, 2012. In instances where a number of samples were taken from sites in a catchment, mean concentrations were estimated for each site. If a measured concentration was reported as < LOD then half of the LOD was used in the calculation of means.

Figure 2. Box and whisker plots (indicating median, upper and lower quartile and maximum and minimum values) of PEC/PNEC ratios for A) a range of APIs, obtained from LF-2000-WQX exposure predictions for 2950 river reaches across 22 large river catchments in England and Wales and PNEC values derived from published literature on the effects of the study compounds on aquatic organisms. Removal rates for the grey bars were based on non-detect data so are a 'worst' case indication of risks; and B) for ibuprofen in the individual 18 large river catchments modelled in England and Wales.

Table 1.

Compound	Class	Use in UK in 2009 (Kg/yr)	Site 1	Site 2	Site 3	Site 4
Atenolol	β -blocker	32944	43.8 (18.1 – 66.3)	54.2 (31.2 – 91.2)	26.7 (8.2 – 67.6)	41.1 (19.6 – 114)
Carbamazepine	anti-epileptic	49781	103.6 (49.4 – 199)	138.8(45.0 – 277)	272.3 (34.3 – 555)	182.6 (16.4 – 480)
Cyclophosphamide	chemotherapy agent	281	<1	<1	<1	<1
Diclofenac	non steroidal anti-inflammatory	34720	10.3 (<10 – 24.3)	18.1 (<10 – 39.0)	20.5 (<10 – 76.3)	15.9 (<10 – 47.1)
Fluoxetine	antidepressant	6377	<5	<5	<5	<5
Furosemide	diuretic	20872	10.2 (<5 – 28.9)	19.8 (6.59 – 43.1)	9.1 (<5 – 36.0)	17.4 (5.34 – 63.5)
Ibuprofen	non steroidal anti-inflammatory	277466	17.6 (6.33 – 30.8)	11.8 (<2 – 38.4)	8.4 (<2 – 21.5)	18.2 (<2 – 38.2)
Ketoprofen	non steroidal anti-inflammatory	1878	<1	<1	<1	<1
Naproxen	non steroidal anti-inflammatory	67672	18.2 (10.2 – 26.4)	18.1 (6.93 – 42.2)	13.6 (4.85 – 28.9)	23.1 (11.1 – 44.4)
Orlistat	anti-obesity	16669	<10	<10	<10	<10
Simvastatin	hypolipidemic	50070	<50	<50	<50	<50
Trimethoprim	antibiotic	13094	10.0 (<5 – 13.8)	9.5 (<5 – 13.8)	4.1 (<5 – 8.27)	8.9 (<5 – 26.4)

Table 2.

Site	Location	Population	Number of treatment plants upstream of sampling point	Types of STPs [†]	Average water residence between discharge and sampling (d)
1	Midlands	402227	17	SAS 1 SB 5 TA 3 TB 8	1.27
2	Southern England	2071445	81	SAS 12 SB 22 TA 19 TB 28	2.33
3	Southern England	395581	27	SAS 2 SB 11 TA 8 TB 6	2.42
4	South East England	177801	14	SAS 2 SB 3 TA 4 TB 5	1.46

[†]General classification of sewage treatment plants: SAS - Secondary Activated Sludge; SB - secondary biological filter; TA - Activated Sludge with tertiary treatment; TB - Biological filter with tertiary treatment.

Table 3.

Compound	Proportion of administered compound excreted by patient (%)	Proportion of compound removed in wastewater treatment plants	Dissipation half-life in receiving water (d)
Atenolol	69 – 96	-93 - 97	3 - 30
Carbamazepine	26 – 31	-122 – 58	82 - 100
Cyclophosphamide	2.5 – 20	0	43
Diclofenac	6 – 26	-143 – 80	5
Fluoxetine	20 – 26	33	112 – 113
Furosemide	90	-119 – 75	-
Ibuprofen	11 – 47	52 – 99.7	~20
Ketoprofen	-	40–100	-
Naproxen	0.6 – 5.6	48 – 93	10.2 – 14.6
Orlistat	83.1	~90	-
Simvastatin	-	-17 – 91	7.8
Trimethoprim	50 – 70	-40 – 40.4	5.7 – 100

Data collated from: Anderson et al., 2004; Andreozzi et al., 2003; Araujo et al., 2011; Bagley et al., 1973; Boxall et al., 2002; Bürge et al., 2003; Buser et al., 1999; Garcia-Ac et al., 2009; ; Gros et al., 2010; Heberer et al., 2002; Kasprzyk Hordern, 2012; Kovalova et al., 2011; Kwon; & Armbrust, 2006; Küster et al., 2010; Lam et al., 2004, LeClerq et al., 2009; Lee et al., 2009; Lienert et al., 2007; Paffoni et al., 2006, Paxeus, 2004; Piecha et al., 2010; Roche, unpublished; Runkel et al., 1972; Sipma et al., 2010; Ternes et al., 2001; Upton et al., 1980; Wu et al., 2011; Yamamoto, 2009; Zhi et al., 1995; Zuccato et al., 2001.

Table 4.

Compound	River catchments	References
Atenolol	Blackwater, Derwent, Ely, Great Ouse, Taff, Thames	1,2
Carbamazepine	Blackwater, Derwent, Ely, Great Ouse, Taff, Thames	1-3
Diclofenac	Blackwater, Derwent, Ely, Great Ouse, Lea, Nene, Sussex Ouse, Taff, Thames, Welland	1-4
Furosemide	Blackwater, Derwent, Ely, Great Ouse, Taff, Thames	1,2
Ibuprofen	Blackwater, Derwent, Ely, Great Ouse, Lea, Nene, Sussex Ouse, Taff, Thames, Tyne, Welland	1-6
Naproxen	Blackwater, Derwent, Ely, Great Ouse, Taff, Thames	1,2
Trimethoprim	Blackwater, Derwent, Ely, Great Ouse, Lea, Nene, Taff, Thames, Tyne, Welland	1-3,6

1-Kasprzyk Hordern et al., (2008); 2- Boxall et al., (2012); Zhang and Zhou (2007); 4- Environment Agency (2003); 5 – Bound and Volvoulis (2006); 6 – Roberts and Thomas (2006)

Table 5.

	Test	EC50 (mg/l)	NOEC (mg/l)	AF (REACH)	PNEC (µg/l)	Source
Atenolol	<i>Pseudokirchneriella subcapitata</i> 72 h growth		128.8			Küster et al., 2010
	<i>Daphnia magna</i> 21 d reproduction		8.872			Küster et al., 2010
	<i>Daphnia magna</i> 21 d second generation reproduction test started with 1 st gen. brood		1.48	10	148	Küster et al., 2010
	<i>Pimephales promelas</i> 32 d hatching, survival, growth		3.2			Winter et al., 2008
Carbamazepine	<i>Daphnia magna</i> 48 h	13.8				Ferrari et al., 2009
	<i>Pseudokirchneriella subcapitata</i> 96 h growth		100			Ferrari et al., 2003
	<i>Ceriodaphnia dubia</i> 7 d reproduction		0.025	10	2.5	
	<i>Danio rerio</i> 10 d ELS		25			
Cyclophosphamide	<i>Pseudokirchneriella subcapitata</i> 96 h growth	930		100	560	Zounkova et al., 2007; SFT, 2006
	<i>Daphnia magna</i> 48 h immobilisation	>1000				
	<i>Daphnia magna</i> reproduction		56			
Diclofenac	Proposed EQS under the Water Framework Directive				0.1	SCHER, 2011a
	Rainbow trout reproduction		0.32	10	32	Novartis (personal comm)
	Zebra fish reproduction		0.32	10	32	
Fluoxetine	<i>Daphnia magna</i> chronic		0.089			Brooks et al., 2005; Lister et al., 2009; Oaks et al., 2010
	<i>Danio rerio</i> reproduction		0.0032			
	<i>Desmodesmus subspicatus</i> growth		0.0006	10	0.06	
	<i>Thamnocephalus platyurus</i> 24 h		0.76			Nalecz-Jawecki, 2007
Furosemide	<i>Pseudokirchneriella subcapitata</i> 96 h growth		70	1000	70	Isidori et al., 2006
	<i>Daphnia magna</i> 48 h immobilisation	60.62				
Ibuprofen	<i>Scenedesmus subspicatus</i> 72 h growth	342		10	0.01	Han et al., 2010; Cleuvers, 2004
	<i>Daphnia magna</i> 21 d reproduction		<1.23			
	<i>Oryzias latipes</i> 120 d (post hatch) survival		0.0001			
Naproxen	<i>Daphnia magna</i> 48 h	37				Straub and Stewart, 2007
	<i>Lepomis macrochirus</i> 96h	560				
	<i>Pseudokirchneriella subcapitata</i> 96 h growth		0.032			Brun et al., 2006
	<i>Ceriodaphnia dubia</i> 7 d reproduction		0.032	100		
	ERC value developed from chronic studies				4.2	Murray-Smith et al, 2012

	Test	EC50 (mg/l)	NOEC (mg/l)	AF (REACH)	PNEC (µg/l)	Source
Orlistat	<i>Selenastrum capricornutum</i> 10 d		1.92			GSK 2008
	<i>Daphnia magna</i> 21 d NOEC		0.0016	50	0.032	
Simvastatin	<i>Oncorhynchus mykiss</i> 96 h	>18.5				Delorenzo and Fleming, 2008 Key et al., 2009
	<i>Dunaliella tertiolecta</i> 96 h EC50	22.8				
	<i>Fundulus heteroclitus</i> 96 h EC50	2.68				
Trimethoprim	<i>Palaemonetes pugio</i>	1.18		1000	1.20	Yang et al., 2008 Ando et al., 2007 Park & Choi, 2008 Kim et al., 2007
	<i>Pseudokirchneriella subcapitata</i> 72 h		16			
	8 species of cyanobacteria 144 h		3.1–200	50	62	
	<i>Daphnia magna</i> 21 d reproduction		6			
	<i>Oryzias latipes</i> 96 h	>100	20			

Table 6.

Compound	Removal between point of use and point of monitoring using inverse modelling (%)	'Best' and 'Worst' case removal between point of use and monitoring points based on published metabolism, treatment and dissipation data (%)	Inverse modelled removal rate corrected for in-stream dissipation (%)
Atenolol	93.92 (86.94-97.27)	4.0 – 97.9	90.92 (81.87-95.28)
Carbamazepine	90.63 (85.20-96.07)	69.0 – 89.1	90.01 (84.89-93.95)
Cyclophosphamide	95.36 (93.75-96.73)	—	94.74 (93.75-95.38)
Diclofenac	98.24 (97.20-99.42)	74.0 – 95.2	97.64 (96.51-99.00)
Fluoxetine	98.97 (98.63-99.26)	82.6 – 86.6	98.87 (98.66-99.03)
Furosemide	98.18 (96.67-99.10)	10 – 77.5	97.67 (95.81-98.82)
Ibuprofen	99.86 (99.81-99.92)	77.4 – 99.97	99.84 (99.80-99.91)
Ketoprofen	99.31 (99.07-99.50)	—	99.25 (99.11-99.37)
Naproxen	99.18 (98.74-99.48)	97.1 - 99.6	99.01 (98.59-99.31)
Orlistat	98.11 (97.45-98.63)	—	97.94 (97.52-98.30)
Simvastatin	98.42 (97.86-99.02)	—	98.01 (97.52-98.38)
Trimethoprim	97.85 (96.39-99.07)	30-70.2	97.14 (95.54-98.73)

Table 7.

	Median concentration (ng/l)		Lower quartile		Upper quartile	
			concentration (ng/l)		concentration (ng/l)	
	Monitoring	Modelled	Monitoring	Modelled	Monitoring	Modelled
	data	data	data	data	data	data
Atenolol	140	92	46	43	435	172
Carbamazepine	61	193	14.5	89	265	321
Diclofenac	20	24	6.4	11	61	46
Furosemide	10.4	19	3.1	8.9	34	32
Ibuprofen	125	14	25	6.4	475	26
Naproxen	13	24	4.2	11	42	46
Trimethoprim	6.7	11	2.1	4.9	21	21




Fig. 1





Fig. 2